基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 医药中间体 杂环化合物 吡啶类化合物 羟基吡啶 4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑 化合物 SB202190
  • 化合物 SB202190|T2301

化合物 SB202190|T2301

SB 202190
152121-30-7
839 25瓶 起订
1675 100瓶 起订
997 50瓶 起订
333 1瓶 起订
467 10瓶 起订
2683 200瓶 起订
上海 更新日期:2024-09-14

TargetMol中国(陶术生物)

VIP12年
联系人:邵小姐
电话:021-021-33632979拨打
手机:15002134094 拨打
邮箱:marketing@targetmol.com

产品详情:

中文名称:
化合物 SB202190
英文名称:
SB 202190
CAS号:
152121-30-7
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.84%
产品类别:
抑制剂
货号:
T2301

Product Introduction

Bioactivity

名称SB 202190
描述SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
细胞实验For transfection, A549 cells were seeded in 6-well plates to obtain 30% confluence at the time of transfection. Xtreme siRNA transfection reagent was used to transfect siRNA to a final concentration of 100 nM. Inhibition of gene expression by siRNA was determined after 48 hours by Western analysis. Cells were harvested, and the nuclear extract or total cell lysate was assayed for AP-1 DNA binding or Western blotting, respectively. HEK293T cells were cultured in complete DMEM. phCMV2-HA-MLK3 was transfected into HEK293T cells using genejammer transfection reagent using manufacturer's instructions. After 48 hours, cells were either untreated or treated with 5 or 10 μM SB202190 or SB203580 for 4 hours. Following treatment cell lysates were prepared using lysis buffer (50 mM Tris-HCl at pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 50 mM NaF, 10 mM sodium pyrophosphate, 25 mM β- glycerophosphate, 1 mM PMSF, 30 μL/mL aprotinin, and 1 mM Na3VO4). 500 μg of total protein was immunoprecipitated with anti-HA-agarose conjugate. Phospho-MLK3 (Thr277/Ser281) was detected in western blotting using phosphospecific antibodies. The expression vector was transfected into HEK293T cells using Genejammer as stated earlier. After 48 hours, cell lysates was prepared and Flag-MKK7 was immunoprecipitated using anti-Flag-agarose conjugate. The Flag-MKK7 was used as a substrate for MLK3 kinase assay [3].
激酶实验All protein kinase activities were linear with respect to time in every incubation. Assays were performed either manually for 10 min at 30 °C in 50 μl incubations using [γ-32P]ATP or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 min at ambient temperature in 25 μl incubations using [γ-32P]ATP. The concentrations of ATP and magnesium acetate were 0.1 mM and 10 mM respectively, unless stated otherwise. This concentration of ATP is 5–10-fold higher than the Km for ATP of most of the protein kinases studied in the present paper, but lower than the normal intracellular concentration, which is in the millimolar range. All assays were initiated with MgATP. Manual assays were terminated by spotting aliquots of each incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays were terminated by the addition of 5 μl of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers were then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity [1].
动物实验The pharmacological efficacy of SB-ULS-LZM was evaluated in the unilateral ischemia-reperfusion (I/R) rat model. At 2 h before the ischemia procedure, rats were injected with SB-ULS-LZM (32 mg/kg. conjugate, equivalent to 752 g/kg SB202190), vehicle (5% glucose), or free SB202190 (800 g/kg). SB-ULS-LZM was dissolved in 5% glucose, whereas SB202190 was dissolved in 20% hydroxypropyl-β-cyclodextrin solution with 5% dimethyl sulfoxide as described earlier. Compounds were administered i.v. via the penis vein as described above. Animals were allowed to recover and placed back into the cages until the induction of renal ischemia. Rats were operated, and the renal artery and vein were clamped under microscope to stop renal blood flow. After 45 min, clamps were removed, and reperfusion of the kidney was observed before closing of the wound. Sham-operated animals (n 3) received the same surgical procedure, with the exception of ischemia, and were included as a control group. After 4 days, animals were sacrificed, and blood samples were collected from the abdominal aorta. Kidneys were isolated after gently flushing the organs with saline and preserved in 4% formalin for preparation of paraffin-embedded sections or frozen in ice-cold isopentane for preparation of cryosections [2].
体外活性方法:人 Tenon 成纤维细胞用 SB 202190 (5-50 μM) 处理,使用 MTT assay 检测细胞活力。 结果:SB 202190 对细胞有毒性,IC50 为 17.2 μM。[1] 方法:人脐静脉内皮细胞 HUVEC 用 SB 202190 (0.1-10 μM) 处理 6-48 h,使用 Western Blot 方法检测靶点蛋白表达水平。 结果:SB 202190 孵育 24 小时后,LC3A/B-I 转化为 PE 偶联的 LC3A/B-II 以浓度依赖的方式增加。[2]
体内活性方法:为研究 p38 MAPK 在急性内毒素血症小鼠中的作用,将 SB 202190 (2 mg/kg) 腹腔注射给 C57BL/6 小鼠,30 min 后注射 LPS (10 mg/kg)。 结果:SB 202190 预处理可降低 TNF-α水平,显著逆转 LPS 诱导的左心室抑制,降低 LPS 诱导的死亡率。[3] 方法:为检测体内抗肿瘤活性,将 SB 202190 (5 mg/kg) 和 OSI-027 (10 mg/kg) 腹腔注射给携带人 CRC 肿瘤 SW620 的 BALB/c 小鼠,每天一次,持续十天。 结果:单独使用 SB 202190 增强了 SW620 异种移植物的肿瘤增殖和肿瘤负荷。SB 202190 和 OSI-027 的联合显著减弱了异种移植物肿瘤的生长。[4]
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.31 mg/mL (9.99 mM), Working solution is recommended to be prepared and used immediately.
DMSO : 50 mg/mL (150.9 mM)
关键字Apoptosis | colorectal | Autophagy | inhibit | SB 202190 | Inhibitor | memory | ATP | anti-cancer | learning | SB-202190 | pocket | spatial | deficits | p38 MAPK
相关产品Guanidine hydrochloride | Naringin | Taurine | Gefitinib | Hydroxychloroquine | 5-Fluorouracil | Curcumin | Stavudine | Tributyrin | L-Ascorbic acid | Paeonol | Sodium 4-phenylbutyrate
相关库抑制剂库 | 抗癌活性化合物库 | 经典已知活性库 | 已知活性化合物库 | 成骨分子库 | 激酶抑制剂库 | MAPK 抑制剂库 | 抗衰老化合物库 | 抗肝癌化合物库 | 疼痛相关化合物库
FHPI|||SB202190|TargetMol

公司简介

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起,为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部,化学事业部,生物事业部和新材料部。 从虚拟筛选到实体化合物分子供应;从商业化产品销售到个性化定制合成;从对明确靶点的分子筛选到对明确分子的多靶点筛选,从高通量筛选到化学结构优化,我们都可以满足您的科研用品及技术服务的需求。 经过在中国市场五年的精心耕耘,我们已成为筛选化合物领域优秀的供应商,为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期 (12年)
注册资本 566.2651万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,试剂,定制,服务
主营行业 化学试剂,生物活性小分子

化合物 SB202190相关厂家报价 更多

  • SB 202190
  • SB 202190
  • 南京百鑫德诺生物科技有限公司 VIP
  • 2024-09-23
  • 询价
  • SB 202190
  • SB 202190
  • 武汉艾美捷科技有限公司 VIP
  • 2024-08-15
  • 询价
内容声明
拨打电话 立即询价